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Abstract
Objective: To evaluate the prevalence and natural course of autoimmune and non-autoimmune subclinical 
hypothyroidism (SH) in Down syndrome (DS) children and adolescents.
Design: Prospective multicenter study.
Methods: For the study, 101 DS patients with SH (TSH 5–10 mIU/L; FT4 12–22 pmol/L), aged 2–17 years at SH diagnosis 
were enrolled. Annual monitoring of TSH, FT4, BMI, height, and L-thyroxine dose was recorded for 5 years. Thyroid 
autoimmunity was tested at diagnosis and at the end of follow-up.
Results: Thirty-seven out of 101 patients displayed autoantibody positivity (group A); the remaining 64 were classified as 
non-autoimmune SH (group B). Group A was characterized by higher median age at SH diagnosis and by more frequent 
family history of thyroid disease (6.6 vs 4.7 years, P = 0.001; 32.4% vs 7.8%, P = 0.001 respectively), whereas congenital 
heart defects were more common in group B (65.6% vs 43.2%, P = 0.028). Gender, median BMI (SDS), height (SDS), FT4, 
and TSH were similar in both groups. At the end of follow-up: 35.1% of group A patients developed overt hypothyroidism 
(OH) vs 17.2% of group B (P = 0.041); 31.25% of group B vs 10.8% of group A became biochemically euthyroid (P = 0.02); 
and 37.8% of group A vs 51.5% of group B still had SH condition (P = 0.183). Logistic regression suggested autoimmunity 
(OR = 3.2) and baseline TSH values (OR = 1.13) as predictive factors of the evolution from SH to OH.
Conclusions: In DS children, non-autoimmune SH showed higher prevalence and earlier onset. The risk of thyroid 
function deterioration over time seems to be influenced by thyroid autoimmunity and higher baseline TSH values.
Introduction
Subclinical hypothyroidism (SH) is a biochemical 
condition defined by mildly elevated serum TSH 
concentrations associated with normal circulating levels 
of thyroid hormones.
Data on SH in the general pediatric population are 
scarce; it seems to be a relatively rare condition in children 
and adolescents (1.7–2.9%), usually characterized by a 
self-limiting and remitting process with spontaneous 
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normalization or stabilization of TSH values in the 
majority of cases (up to 88%) (1, 2, 3).
It has already been documented that underlying 
Hashimoto thyroiditis (HT) can negatively affect the 
natural course of SH by increasing the risk of thyroid 
function deterioration over time. Moreover, the 
association with chromosomopathies such as Turner 
syndrome or Down syndrome (DS) may impair the 
outcome of HT-related SH by further increasing the risk of 
progression to overt hypothyroidism (4, 5, 6).
With respect to DS, it is well-known thyroid 
dysfunction which is much more prevalent and occurs 
earlier than in the general population. SH is the most 
common thyroid abnormality in DS children, with 
prevalence ranging from 25.3% to 60% depending on 
studies (7, 8, 9, 10). The etiology of SH in DS remains 
still not completely clarified. The most obvious and 
important hypothesis to explain early onset SH is based 
on a generally mild and non-autoimmune thyroid 
dysfunction, probably caused by a congenital alteration 
in the regulation of the thyroid gland itself. This finding 
at group level suggests that it could be in direct relation 
to the trisomy of chromosome 21 condition (11, 12, 13, 
14, 15). Autoimmunity is also among the hypothesized 
causes, appearing predominantly from school-age years 
onward (9, 10, 16). Indeed, it must be considered that DS 
children are exposed to an increased risk of autoimmune 
disorders affecting both endocrine and non-endocrine 
organs. As a result, HT is one of the most frequent causes 
of persistent SH, characterized by peculiar features in DS: 
it is much more common, occurs earlier, without gender 
predominance, with a more severe biochemical onset 
and clinical course, and with a higher rate of conversion 
to Graves disease over time than the general population 
(5, 17, 18).
SH in DS children remains relatively unknown because 
of the scarcity of specific literature data on pathogenesis, 
natural history, and clinical significance. Consequently, 
the effectiveness of L-T4 administration and the 
management of these patients is still controversial (7, 19). 
The American Academy of Pediatrics (AAP) recommends 
that thyroid function should be evaluated at 6 and 12 
months and then annually in all DS children, with 
increased frequency in SH (20). Despite these guidelines, 
data showed that up to 25% of children >1 year do not 
receive recommended screening (21).
Until now, SH in DS appears to be mainly a 
transient condition, with a rate of evolution toward 
overt hypothyroidism reported in less than 50% of cases 
(14, 16, 22).
Our prospective study aims to assess relative 
prevalence and the natural course of autoimmune and 
non-autoimmune SH in a large cohort of DS children 
and adolescents, looking for any predictive factors of 
spontaneous evolution of thyroid function over time.
Subjects and methods
Study population
The study consisted of 101 children and adolescents with 
DS and SH, who were followed in our outpatient clinics 
of pediatric endocrinology centers during the period 
2013–2018. The following inclusion criteria was carried 
out: (1.) chronological age ≥2 and <17 years at the time 
of SH diagnosis and (2.) TSH serum levels at SH diagnosis 
ranging between 5 and 10 mU/L associated with normal 
FT4 (reference range 12.0–22.0 pmol/L). DS children 
with congenital hypothyroidism or early onset isolated 
hyperthyrotropinemia (in the first 2 years of life) were 
excluded from the study.
The entire series was divided into two groups, 
according to whether the etiology of SH was autoimmune 
(group A) or non-autoimmune (group B). Therefore, 
patients of group A were positive for thyroglobulin and/
or thyroid peroxidase serum autoantibodies (TGAbs and 
TPOAbs respectively), while the autoimmunity profile was 
entirely negative in group B.
Group A consisted of 37 patients (19 girls and 18 
boys), 30 of which were prepubertal and 7 pubertal. Group 
B consisted of 64 patients (30 girls and 34 boys), only one 
of which was pubertal.
Study design
SH SD patients who fulfilled the inclusion criteria reported 
above were enrolled for this prospective multicenter study.
From the time of recruitment, the participants were 
evaluated every 12 months, for a period of 5 years.
Initial evaluation at SH diagnosis included: family 
history for thyroid disease, auxological evaluation (height 
H, BMI) and pubertal status, presence of congenital heart 
disease, thyroid function, and autoimmunity tests (TSH, 
FT4, TGAbs and TPOAbs serum levels). At each annual 
examination H, BMI, TSH, and FT4 were recorded. 
Thyroid autoimmunity profile was re-tested at the end of 
follow-up.
The possible occurrence of other autoimmune diseases 
was monitored throughout the 5-year observation period.
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In the patients who exhibited an increase in TSH levels 
above 10 mU/L and/or a pathological decrease of FT4 levels 
to <12 pmol/L, L-T4 treatment was started according to 
our guidelines (23) and other recommendations (24, 25).
In the patients who exhibited a dramatic decrease of 
TSH serum levels to <0.3 mIU/L and/or an increase of FT4 
to >22 pmol/L, methimazole treatment was begun.
According to thyroid function tests, patients were 
classified into the following biochemical patterns: 
euthyroidism (both TSH and FT4 within normal limits); 
SH (normal FT4, as opposed to elevated TSH); overt 
hypothyroidism, OH (elevated TSH with low FT4); and 
hyperthyroidism (suppressed TSH, as opposed to either 
normal or elevated FT4).
Methods
Serum levels of TSH (reference range 0.3–4.5 mIU/L) 
and FT4 (reference range 12.0–22.0 pmol/L) were 
measured by RIA methods. Thyroid autoimmunity was 
investigated by the measurement of TPOAbs (reference 
range 0–20 IU/mL) and TGAbs (reference range 0–30 IU/
mL) by chemiluminescent immunometric assays. TRABs 
serum levels (reference range 0–4 IU/mL) were measured 
only in the patients who, during follow-up, displayed 
a hyperthyroid biochemical evolution and underwent 
methimazole therapy (26, 27).
Auxological assessment was based on H measurement 
and BMI calculation. Standing H was measured with a 
Harpenden stadiometer (Holtain Ltd, Crymych, Dyfed, 
UK). BMI was calculated as weight divided by height 
squared (kg/m2). To allow the comparison between 
different ages and genders, H and BMI were expressed as 
S.D. scores (SDS). Italian specific growth charts for Down 
syndrome are not available, so the auxological parameters 
were measured according to the Italian standards assessed 
by Cacciari et al. (28).
Statistical analysis
Numerical data were expressed as mean, s.d., median and 
range; categorical variables were expressed as absolute 
frequency and percentage.
Non-parametric approach was used since the 
numerical variables were not normally distributed, such 
as verified by Kolmogorov Smirnov test.
In order to evaluate the existence of statistically 
significant differences in the time (basal vs T1, T2, T3, T4, 
and T5) for each numerical variable, the Wilcoxon test 
was applied, both for whole sample and for each group 
(autoimmune and non-autoimmune); for categorical 
variable ‘therapy’ the Mc Nemar test was applied. 
The same analysis was performed within the group of 
untreated patients.
Statistical comparisons between autoimmune and non-
autoimmune patients were performed using Mann Whitney 
test (for numerical variables) and Chi-Square test or exact 
Fisher test, when appropriate (for categorical variables).
Univariate logistic regression models were estimated 
in order to individuate predictive factors of overt 
hypothyroidism; a multivariate logistic regression model 
was estimated in order to identify independent predictive 
factors of overt hypothyroidism.
In order to describe the onset of overt hypothyroidism 
over time, the Kaplan–Meier curve was made for both 
groups; moreover, the Log-Rank test was applied to 
compare the curves (autoimmune vs non-autoimmune).
Statistical analyses were performed using IBM SPSS 
Statistics for Windows, Version 21. A P-value smaller than 
0.05 was considered statistically significant.
The study design was approved by the ethical 
committee of the University hospital AOU Policlinico 
‘Gaetano Martino’ and by the local ethical committees of 
the hospitals participating to the study. Informed consent 
was obtained from the children’s parents. The appropriate 
consent was also obtained earlier from the study group 
for thyroid diseases of the Italian Society for Pediatric 
Endocrinology and Diabetology.
Results
Main data at diagnosis of SH
The average age at the time of diagnosis of SH was 
significantly higher in group A than in group B. 
Consequently, the prevalence rate of patients who had 
entered puberty was lower in group B than in group A 
(Table 1).
A family history of thyroid disease was more common 
in group A. Instead, a personal history of congenital heart 
disease was detected more frequently among patients in 
group B. None of the cardiopathic patients underwent 
therapy with amiodarone or other drugs which could 
have affected thyroid function. BMI, height, FT4, and TSH 
values at follow-up initiation did not significantly differ 
in these two groups.
Group A was the only group to show any association 
with other autoimmune diseases: four patients had celiac 
disease, two patients had diabetes mellitus type 1, and one 
patient had vitiligo.
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Thyroid function patterns at the end of 
5-year follow-up
Overall, 24 out of 101 patients normalized their TSH 
concentrations (<5 mUI/L) during the 5-year observation 
period, with significantly higher frequency registered 
among group B compared to group A (31.25% vs 10.8%, 
P = 0.02). A deterioration of thyroid function to OH 
was observed in 24 patients; this event was instead 
significantly more frequent in group A than in group B 
(35.1% vs 17.2%, P = 0.004) (Fig. 1).
The majority of patients in both groups (47 out of 
101) maintained, over time, a condition of SH (37.8% in 
group A vs 51.5% in group B, P = 0.183).
Only 6 (16.2%) patients in group A and no-one 
of group B became overtly hyperthyroid, displaying 
a picture of GD with TRABs positivity and requiring 
methimazole therapy.
Factors influencing the deterioration of thyroid 
function over time
The patients in group A displayed a greater risk of 
developing overt hypothyroidism in comparison to 
group B (OR = 3.2), confirmed by both univariate and 
multivariate regression model. This suggests that the 
autoimmune etiology of SH could be regarded as an 
independent predictive factor responsible for the 
deterioration of thyroid function over time. This finding 
was also highlighted by using the Kaplan–Meier curve 
(Fig. 2): the progression from SH to OH was significantly 
more frequent among the patients in group A as opposed 
to the patients in group B (P = 0.011).
Moreover, the baseline TSH value was higher in 
patients who developed overt hypothyroidism; this 
predictive factor was highlighted by the univariate 
regression, even thought it was not confirmed by the 
multivariate regression.
There was no evidence that the others factors involved 
– gender, age at diagnosis of SH, presence of congenital 
heart disease, family history for thyroid diseases, baseline 
auxological parameters and FT4 values – had any influence 
on the final outcome.
Table 1 Mean ± SDS and number (N°) with percentage (%) data collected at the start of follow-up in the overall study population of 
Down syndrome children with subclinical hypothyroidism (SH), in Group A (autoimmune SH) and in Group B (non–autoimmune SH).
Total study population Group A Group B P
n (%) 101 (100%) 37 (36.6%) 64 (63.4%)
Gender
 Female 49 (48.5%) 19 (51.4%) 30 (46.9%) 0.665
 Male 52 (51.5%) 18 (48.6%) 34 (53.1%) 0.665
Congenital cardiopathy 58 (57.4%) 16 (43.2%) 42 (65.6%) 0.028
Family history of thyroid disease 17 (16.8%) 12 (32.4%) 5 (7.8%) 0.001
Age 5.4 ± 2.9 6.6 ± 3.27 4.7 ± 2.86 0.001
TSH UI/mL 7.4 ± 4.2 8.5 ± 5.5 6.8 ± 3.1 0.126
FT4 pmol/L 15.1 ± 5.9 14.9 ± 8.0 15.2 ± 4.0 0.091
H (SDS) −1.7 ± 1.2 −1.5 ± 1.5 −1.7 ± 1.0 0.247
BMI (SDS) 0.9 ± 0.9 1.1 ± 0.9 0.7 ± 0.9 0.12
Pubertal patients 8 (7.9%) 7 (18.9%) 1 (1.6%) 0.002
Celiac disease 4 (4%) 4 (10.8%) 0 0.004
DMT1 2 (2%) 2 (5.4%) 0 0.043
Vitiligo 1 (1%) 1 (2.7%) 0 0.155
P between groups A and B.
DMT1, diabetes mellitus type 1; H, height.
Figure 1
Outcome of subclinical hypothyroidism (SH) at the end of 
5-year follow-up: different biochemical patterns of thyroid 
function detected in Group A (autoimmune SH), Group B 
(non-autoimmune SH), and total population (Group A + B).
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Comparison between treated and 
untreated patients
Overall, 48 patients of 101 required L-T4 therapy during 
the 5-year observation period. The prevalence rate of L-T4 
treated patients was higher in group A than in group B 
(66.6% vs 33.3%). The remaining 53 patients had never 
required replacement therapy during the study protocol; 
of these, 86.8% formed part of group B compared to 13.2% 
within group A (Table 2).
Among the L-T4 patients treated, the non-autoimmune 
subgroup portrayed a higher frequency of congenital heart 
diseases and a lower BMI in at SH diagnosis, whereas 
untreated patients displayed a higher H SDS baseline 
value within the autoimmune subgroup. In addition, 
we observed a spontaneous and progressive decrease in 
medium TSH values in untreated patients (Fig. 3).
No significant difference was recorded for the other 
parameters which are detailed in Table 2.
Discussion
There are only a few systematic studies on SH in DS and 
the factors related to its evolution over time are still 
unclear. To the best of our knowledge, this is the first 
prospective study aimed to assess annually, over a period of 
Figure 2
Kaplan–Meier curves showing that the progression from 
subclinical hypothyroidism (SH) to overt hypothyroidism, 
during the 5-years follow-up, is significantly more frequent in 
Group A (autoimmune SH) than in Group B (non-autoimmune 
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5-years, the natural course of SH in a large pediatric 
cohort with DS, excluding congenital hypothyroidism 
or early onset isolated hyperthyrotropinemia and mainly 
focusing on the comparison between autoimmune and 
non-autoimmune etiology of SH.
The first consideration highlighted by our results is 
that non-autoimmune etiology of SH is prevalent in DS 
children (63.4% of our population never displayed thyroid 
autoantibodies positivity before SH diagnosis nor during 
5 years of follow-up). This finding is in agreement with 
previous studies (8, 9, 14, 22). Hence, SH in DS does not 
appear to be mainly autoimmune-mediated, especially in 
the first years of life. This phenomenon could be explained 
by a non-pathological shift in the normal range of TSH as 
a characteristic of DS, which results in a generally mild 
and transient form of thyroid disfunction at group level, 
as suggested by some authors (11, 12, 13, 29). Indeed, 
the early onset and non-autoimmune SH observed in the 
majority of DS infants is probably due to a congenital 
thyroid alteration, which is directly related to the trisomy 
condition of chromosome 21. Possible mechanisms of 
isolated elevations in TSH levels can include a delayed 
maturation of hypothalamic-pituitary-thyroid axis, an 
inappropriate release of TSH, production of TSH with 
lowered activity, TSH insensitivity in the thyroid gland, 
and hyper-responsiveness to IFN due to over-expression 
of genes coding for IFN-receptor (7, 14).
Another common feature of DS patients is their higher 
and earlier susceptibility toward autoimmunity than the 
general population (5). This condition frequently results 
in HT, which might be regarded as the second most 
important cause of SH in DS. In particular, autoimmunity 
plays a greater role much later on, during the school-age 
years (16). As registered in the present study, the average 
age of SH diagnosis was higher among patients with 
autoantibodies. As a consequence of the etiology, patients 
with autoimmune SH showed a frequent family history of 
thyroid disease, and seven of them also developed other 
autoimmune diseases over time (diabetes mellitus type 1, 
celiac disease, and vitiligo).
Congenital heart disease (CHD) was more frequently 
reported in group B. The association between CHD and 
thyroid dysfunction is due to the peculiarity of embryonic 
thyroid development, which is closely associated with the 
developing heart: the thyroid reaches its position near the 
base of the neck as a consequence of the heart descent. A 
disturbance of the proliferation and migration of the neural 
crest cells, which are also involved in this process, may 
impair both cardiac and thyroid development (30). These 
common alterations during embryogenesis of both organs 
could explain the earlier onset of thyroid dysfunction 
in non-autoimmune SH and the higher frequence of 
congenital heart disease observed in this group.
Therefore, SH in DS may show different patterns of 
progression. Our study design gave us the opportunity 
to evaluate whether the association with autoimmune 
etiology may modify the natural history of SH. According 
to our results, after a 5-years follow-up period, the most 
common outcome was the persistence of SH condition 
over time, irrespectively of the etiology. SH spontaneous 
resolution in biochemical euthyroidism was most 
frequently detected among non-autoimmune patients 
(31.25% in group B vs 10.8% in group A). In contrast, 
the progression from SH to OH occurred more commonly 
on the basis of autoimmune SH. This finding is clearly 
confirmed not only by multivariate logistic regression 
analysis but also by using Kaplan-Meier curve: the onset 
of OH is an event registered with significantly higher 
frequence among the autoimmune group.
In addition, evaluating the features of treated and 
untreated patients, we mainly recorded that the ones 
who never required L-T4 therapy displayed a spontaneous 
and progressive decrease of medium TSH values over 
time. Finally, only among group A we detected a small 
percentage (16.2%) of patients who became overtly 
hyperthyroid, displaying a picture of GD with TRABs 
positivity, which confirmed that DS children might be 
incline to exhibit a phenotypic metamorphosis from HT 
to GD and to subsequently fluctuate from hypothyroidism 
to hyperthyroidism (31).
Overall, our data could confirm that SH in DS is 
frequently a transitory and benign process, with a rate 
of evolution toward overt hypothyroidism in less than 
Figure 3
Medium TSH levels in untreated Down syndrome patients with 
subclinical hypothyroidism: spontaneous decrease of the 
values during 5-year follow-up monitoring.
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50% of cases (10, 13, 19). Nevertheless, underlying 
autoimmunity plays an important role and can negatively 
affect the natural course of SH, with both decreased 
probabilities of TSH normalization and increased risk of 
overt thyroid dysfunctions (5, 9, 22, 32).
Moreover, our data highlighted that TSH value 
at diagnosis was significantly higher in patients who 
developed a picture of OH; therefore, this predictive factor 
could be regarded as an early marker of progression into 
the deterioration of thyroid function.
Based on our results, there was no evidence that the 
others factors involved – gender, age at diagnosis of SH, 
presence of congenital heart disease, family history for 
thyroid diseases, baseline auxological parameters and FT4 
values – had any influence on the final outcome.
In conclusion, in DS children: (1.) non-autoimmune 
SH shows higher prevalence and earlier onset and (2.) the 
risk of thyroid function deterioration over time, from SH 
to OH, seems to be influenced by autoimmune etiology 
and higher baseline TSH values. Taking into consideration 
the high frequency of SH in DS and its natural course, a 
periodic follow-up of thyroid function is recommended 
in these patients.
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